Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCTFree Report) in a research report released on Sunday. The firm issued a hold rating on the stock.

A number of other research analysts have also weighed in on ONCT. Northland Securities reissued a “market perform” rating and issued a $2.00 price objective on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Northland Capmk lowered Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, HC Wainwright cut their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.00.

Read Our Latest Stock Analysis on ONCT

Oncternal Therapeutics Price Performance

Shares of NASDAQ ONCT opened at $1.72 on Friday. The stock has a market capitalization of $5.09 million, a P/E ratio of -0.14 and a beta of 1.33. Oncternal Therapeutics has a 1-year low of $1.05 and a 1-year high of $13.14. The business has a fifty day moving average price of $2.02 and a 200 day moving average price of $5.52.

Oncternal Therapeutics (NASDAQ:ONCTGet Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. During the same period in the prior year, the company posted ($3.00) EPS. As a group, equities research analysts anticipate that Oncternal Therapeutics will post -12.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oncternal Therapeutics

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCTFree Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 16.05% of the stock is owned by hedge funds and other institutional investors.

About Oncternal Therapeutics

(Get Free Report)

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.

Featured Stories

Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.